Reactive Oxygen Species (ROS) is a class of highly reactive oxidants, which participate in many important physiological and pathological processes in organisms, such as cell signaling, inflammatory response, and tumorigenesis. ROS-responsive liposomes can use the oxidation capacity of ROS to achieve changes in polymer structure or properties to achieve the purpose of regulating drug release, improving biocompatibility, and enhancing therapeutic effect. Intelligent, controllable and efficient ROS-stimulated responsive liposomes are the focus of current research and development of drug delivery systems. CD Formulation has advanced lipid preparation technology, and a multi-functional lipid platform has been established to support various studies in drug development.
Reactive Oxygen Species (ROS) are a series of chemically active oxygen-containing molecules, such as hydrogen peroxide (H2O2), superoxide anion (O2-), and hydroxyl radical (·OH), which play an indispensable role in the process of cell signal transduction. Among endogenous ROS, H2O2 is considered to be the most important member, which is mainly produced by mitochondria. Compared with other ROS, H2O2 has relatively lower activity and higher concentration. Abnormally elevated levels of ROS have been detected in many types of diseases, including cancer, inflammation, and neurodegenerative diseases. In healthy cells, the baseline concentration of reactive oxygen species (ROS) is around 20×10-3 μM under normal conditions, but in specific tumors and inflamed tissues, ROS levels can increase to as high as 100 μM. Due to the large differences in ROS levels between disease and normal tissues, many ROS-responsive liposomes have been developed.
Fig.1 Schematic diagram of ROS-responsive liposomes in targeted drug delivery. (Lou J, et al., 2022)
The ROS-responsive liposome system is designed to trigger drug release at high ROS levels. Our ROS-responsive liposome development platform enables the formulation of functional liposomes for different diseases, including drugs for atherosclerotic lesion areas, tumor drugs, diabetes complications, Cardiac repair disorders after myocardial ischemia-reperfusion (MI/R) injury, etc. Numerous ROS-responsive materials are available, including thioether, selenium, tellurium, thioketone, polysaccharide, aminoacrylate, borate, peroxalate, and polyproline.
In addition to single ROS-responsive liposomes, we can offer multiple stimulus-responsive liposomes, including ROS/GSH/ multi-responsive liposomes, pH/ROS dual-responsive liposomes, etc.
We can offer composites of heat-sensitive liposome hydrogels and ROS-responsive liposome hydrogels that enable precise sequential drug release to enhance molecularly targeted therapy and enhance immune activation.
The release and response rate of ROS liposomes are systematically evaluated with our proprietary ROS-responsive in vitro and in vivo drug release evaluation platform, designed to provide high-quality ROS-responsive liposomes.
Mainly for characterization services: particle size, potential, encapsulation rate, drug loading, etc.
Items | Detailed Information |
Physicochemical characterization |
|
The study of ROS responsiveness and drug release rate |
|
Multiple stimuli responsive liposome development |
|
Multi-treatment strategy development |
|
Technology: ROS-responsive liposome for the delivery of Nrf2 agonist dimethyl fumarate (DMF) in fibrotic lung technique
Journal: Journal of Nanobiotechnology
IF: 11.5
Published: 2022
Results: In this study, the authors aim to design a ROS-responsive liposome for delivering Nrf2 agonist DMF in the fibrotic lung. In addition, they investigated its therapeutic effect on pulmonary fibrosis and macrophage activation. ROS-responsive DSPE-TK-PEG@DMF liposomes (DTP@DMF NPs) loaded with DMF were synthesized. They found that DTP@DMF NPs can reduce macrophage-mediated fibroblast to myofibroblast transformation and extracellular matrix deposition by upregulating Nrf2 signaling, thereby alleviating pulmonary fibrosis. This ROS-responsive liposome is expected to be an ideal inhaled drug delivery system in clinical practice.
Fig.2 Illustration of ROS-responsive liposome for fibrotic lung. (Liu, J., et al., 2022)
CD Formulation has developed a professional platform for reactive oxygen species (ROS)-responsive liposomes and can provide customization services. If you need any help, please do not hesitate to contact us.
References